Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
SODIUM PHOSPHATE, MONOBASIC
Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 161 mg
Research docs0Claims0Sources12FunctionFunction pendingIdentifierchebi:37585
Concern score
5/100Low concern based on regulatory listings.
Well researched
How we scored this
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 (low) · high confidence.
Where it appears
Prevalence of SODIUM PHOSPHATE, MONOBASIC in our catalog (fda_ndc).
Products
8
Catalog
Found in these products
Suitability
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Good fit
Evidence read
The published evidence profile currently shaping this ingredient record.
No evidence profiles are attached to this ingredient yet.
Linked research
Primary documents currently linked to this ingredient record.
No linked research documents are attached to this ingredient yet.
Extracted claims
Structured claim signals pulled from linked ingredient research.
No extracted claims are attached to this ingredient yet.
Regulatory status
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 161 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 161 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 13.2 mg
